MedTrace Logo

Resveratrol for Improved Performance in the Elderly

NCT01126229 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2013-12-11

No results posted yet for this study

Summary

The investigators aim to conduct a randomized placebo controlled pilot study to determine whether resveratrol, a dietary ingredient, supplementation is safe and improves memory and physical performance in older adults. Loss in memory and physical performance is a frequent complaint in older adults and a growing public health issue. Additionally, later adulthood is associated with a normative decline in both working and primary memory as well as domains including attention, speed of processing and executive function. Resveratrol is safely tolerated in pre-clinical models and in dose-escalation human studies. It also has demonstrated beneficial effects on memory and performance in pre-clinical models. Therefore, this study will take the next step in understanding the longer-term safety (3 months) and efficacy of resveratrol supplementation on age-related health conditions.

Conditions

  • Memory

Interventions

DIETARY_SUPPLEMENT

Placebo

2 capsules of placebo daily for 12 weeks

DRUG

Low dose Resveratrol

2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient

DRUG

High dose Resveratrol

2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient

Sponsors & Collaborators

  • University of Florida

    lead OTHER

Principal Investigators

  • Todd M. Manini, PhD · University of Florida, Aging and Geriatric Research

  • Stephen M Manini, PhD · University of Florida, Aging and Geriatric Research

Study Design

Allocation
RANDOMIZED
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-11-30
Primary Completion
2012-12-31
Completion
2012-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01126229 on ClinicalTrials.gov